公开(公告)号：US20190022147A1

公开(公告)日：2019-01-24

申请号：US16044256

申请日：2018-07-24

申请人： Creative Medical Technologies, Inc

发明人： Thomas Ichim ,  Amit Patel ,  Santosh Kesari

IPC分类号： A61K35/50 ,  A61P35/00 ,  C12N5/073

摘要： Disclosed are compositions of matter, therapeutic protocols, and cellular reprogramming means to inhibit glioma or other brain neoplasia. In one embodiment the invention provides administration of amniotic fluid derived stem cells at concentrations of 1 million to 200 million administered in a manner to provide a differentiation stimulation, resulting in reduction of malignant potential. In other embodiments, an unexpected synergy of cancer inhibitory soluble factor production is disclosed by combined cultures between amniotic fluid stem cells and monocytes. In all embodiments cells may be autologous or allogeneic. The invention provides means of augmenting efficacy of immunotherapy, chemotherapy, and radiotherapy.

公开(公告)号：US20180085405A1

公开(公告)日：2018-03-29

申请号：US15717810

申请日：2017-09-27

申请人： Creative Medical Technologies, Inc.

发明人： Thomas Ichim ,  Amit Patel ,  Santosh Kesari

IPC分类号： A61K35/50

CPC分类号： A61K35/50 ,  A61K35/545 ,  C12N2502/03

摘要： Disclosed are compositions of matter useful for treatment of stroke derived from amniotic fluid stem cell produced factors. In one embodiment the invention teaches the use of products derived from amniotic fluid stem cells cultured under basal conditions. In another embodiment the invention teaches the utilization of amniotic stem cell derived products from said amniotic stem cells cultured under conditions of stress. Said amniotic stem cell derived products include small molecules, proteins, peptides, conditioned media, microvesicles, including exosomes and apoptotic bodies. In one embodiment, the invention teaches administration of amniotic fluid stem cells that have been exposed to a stress condition.